The company's unique mito-centric approach focuses on restoring the powerhouse of the cell to enable the re-engineering and restoration of neurological function. Asha Therapeutics leverages expertise in computational chemistry and neurobiology to develop novel therapeutics, with lead assets showing efficacy in human cells and murine models of Parkinson's Disease, Alzheimer's Disease, ALS, Multiple System Atrophy, and Stroke.